← Human Trials & Peer-Reviewed Studies
Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes
Plain-language guide to PMID 17157113 (2006): open-label randomized controlled trial study of Insulin Detemir and NPH Insulin (isophane).
Key Facts
- PMID
- 17157113
- Journal
- Clinical therapeutics
- Year
- 2006
- Study type
- Randomized Controlled Trial
- Authors
- Philis-Tsimikas A et al. (6 authors)
- DOI
- 10.1016/j.clinthera.2006.10.020
- Registered trial
- NCT00104182
What This Study Did, in Plain Language
What Was Tested
Researchers studied Insulin Detemir and NPH Insulin (isophane) in this randomized controlled trial publication.
Many patients with poorly controlled type 2 diabetes mellitus (DM) receive, as initial insulin treatment, the addition of a basal formulation to an existing regimen of oral antidiabetic drug (OAD) therapy.
Who Took Part
By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.
Men and women were eligible for participation if they were aged > or =18 years, had a body mass index (BMI) < or =40 kg/m(2), had a diagnosis of type 2 DM of at least 12 months' duration, and were insulin naive.
How the Study Was Run
The researchers set it up as a randomized, open-label, multicenter and parallel-group study.
Because people in this Insulin Detemir study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Everyone knew when Insulin Detemir was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.
More than one site took part, so the participants came from several places.
The Insulin Detemir group and the comparison group ran side by side rather than switching.
This 20-week, multicenter, randomized, open-label, 3-arm, parallel-group trial was conducted at 91 centers across Europe and the United States.
What Was Measured
The subject headings attached to it are Diabetes Mellitus, Type 2, Glycated Hemoglobin and Insulin.
What This Means in Plain Language
The paper is a randomized, open-label and multicenter study of Insulin Detemir and NPH Insulin (isophane).
Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2006 (Clinical therapeutics), a journal based in United States.
More context: the Insulin Detemir compound page and the NPH Insulin (isophane) compound page.
Our Notes on the Compounds
Insulin Detemir: A long-acting basal insulin analog sold as Levemir.
NPH Insulin (isophane): An intermediate-acting insulin made by combining insulin with protamine; also called isophane or NPH insulin (Humulin N, Novolin N).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.